LUCD appears to be a strong prospect, as its product is already in pivotal trial, which is equivalent to a drug Phase III trial if I understand correctly. Its stock price is currently near its all-time low price, and it seems to be because investors feel that the market for their product isn't as robust as they believed a year ago, for whatever reason. The pro stock analysts (for what that's worth) a year ago set the stock's value at $13-18 but this past March lowered it to $7-12. I put in a limit order to buy some shares on Monday.Many penny stocks are risky, but I bought a few shares in this medical diagnostics stock. One share is cheaper than a hamburger and it has good potential.
Everyone is in the investing game to see strong returns - the bigger, the better. However, the prospect of pocketing huge gains usually comes with a caveat; the potential for higher returns is accompanied by added risk, that is just the natural order of things. For those wishing to venture onto...finance.yahoo.com